Novartis’ $1.5 Billion Myricx Deal Tests Oncology Pipeline

Novartis (NYSE:NVS) has made another clear move toward oncology depth, agreeing to acquire U.K.-based Myricx Bio for up to $1.5 billion. The structure includes $1.1 billion upfront and as much as…